PTC THERAPEUTICS, INC. 4

Executive VP and CLO Mark Elliott Boulding exercised 2,813 PTC Therapeutics stock options at $25.69 and sold 2,813 common shares around $72.50 under a Rule 10b5-1 plan, modestly trimming his direct holdings.

On August 17, 2026, Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc., exercised 2,813 stock options at an exercise price of $25.69 per share, acquiring an equal number of common shares, and then sold a total of 2,813 common shares in two open-market transactions at weighted average prices of $72.39 and $72.90 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. The gross value of the option exercise was approximately $72,250, while the gross sale proceeds totaled roughly $204,000, implying an economic gain of about $132,000 before taxes and commissions. Following these transactions, Boulding’s direct ownership in PTC common stock decreased modestly from 108,085 to 105,272 shares, with the retained holdings worth approximately $7.7 million based on the transaction price context. The options exercised were part of a grant originally issued on February 15, 2024 that vests over four years, indicating this activity is consistent with ongoing equity compensation and partial monetization of vested awards rather than a large, discretionary open-market purchase or sale of existing holdings.

Filing Facts

CIK

1070081

Ticker

PTCT

Form

4

Source Type

fda

Accession

0001578852-26-000022

Alert Tier

6